233 related articles for article (PubMed ID: 37034232)
1. Emerging role of engineered exosomes in nonalcoholic fatty liver disease.
Ding J; Xu C; Xu M; He XY; Li WN; He F
World J Hepatol; 2023 Mar; 15(3):386-392. PubMed ID: 37034232
[TBL] [Abstract][Full Text] [Related]
2. microRNA profiles of serum exosomes derived from children with nonalcoholic fatty liver.
Zhang JW; Pan HT
Genes Genomics; 2022 Jul; 44(7):879-888. PubMed ID: 34390467
[TBL] [Abstract][Full Text] [Related]
3. Communication between nonalcoholic fatty liver disease and atherosclerosis: Focusing on exosomes.
Zhao X; Kong X; Cui Z; Zhang Z; Wang M; Liu G; Gao H; Zhang J; Qin W
Eur J Pharm Sci; 2024 Feb; 193():106690. PubMed ID: 38181871
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease: a systematic review.
Rinella ME
JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
[TBL] [Abstract][Full Text] [Related]
5. The role of exosomal miRNA in nonalcoholic fatty liver disease.
Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
J Cell Physiol; 2022 Apr; 237(4):2078-2094. PubMed ID: 35137416
[TBL] [Abstract][Full Text] [Related]
6. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
7. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
8. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Soejima Y; Fukusato T
World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
[TBL] [Abstract][Full Text] [Related]
9. Recent updates on targeting the molecular mediators of NAFLD.
Wang J; Wang L; Zhang XJ; Zhang P; Cai J; She ZG; Li H
J Mol Med (Berl); 2023 Feb; 101(1-2):101-124. PubMed ID: 36792729
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
11. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
14. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
15. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.
Wang GY; Zhang XY; Wang CJ; Guan YF
World J Gastroenterol; 2023 Jan; 29(1):75-95. PubMed ID: 36683713
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
17. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of thymol and vitamin E on nonalcoholic fatty liver disease in male Wistar rats.
Lahmi A; Oryan S; Eidi A; Rohani AH
Braz J Biol; 2023; 84():e268781. PubMed ID: 36629640
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
20. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
Wang L; Liu XE; Zhuang H
Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
